Navigation Links
Recipient of Melanoma Drug in Development Celebrates Two Cancer-Free Years
Date:10/16/2007

KNOXVILLE, Tenn., Oct. 16 /PRNewswire/ -- When eighty-six-year-old Keith Hora went to see Dr. Peter Hersey, a medical oncologist and professor at the University of Newcastle in Australia, he was told he only had three to six months to live. Hora had been diagnosed with stage III melanoma, one of the most difficult to treat forms of cancer.

"Mr. Hora had multiple melanoma reoccurrences in the previously treated area of his face and nothing was helping him, including multiple surgeries to remove the tumors as well as radiation therapy," recalls Dr. Hersey, a fifteen-year member of the World Health Organization's committee on Melanoma. "His tumors kept returning."

Hora was included in a Phase 1 clinical trial of PV-10 conducted by Dr. Hersey. The trials were sponsored by Knoxville, TN-based Provectus Pharmaceuticals. PV-10 is a small molecule oncology agent being investigated by Provectus for treatment of melanoma and other focal forms of cancer.

"When it is injected into tumor tissue, the drug concentrates in the tumor at cytotoxic levels while quickly dissipating from healthy tissue," says Dr. Hersey. "This makes it safer and more effective than some other therapies."

Hora was treated in late 2005 and recalled getting the good news a few weeks later during an ultrasound follow-up that determined the tumors were shrinking. "After being cancer-free for two years, I feel like jumping over a moon," says Hora.

Provectus has begun the next round of testing intended to demonstrate definitively the efficacy of PV-10. The Phase 2 trial will treat up to eighty Stage III/IV melanoma patients at seven or more sites in Australia and the U.S. While PV-10 is currently undergoing clinical trials to treat melanoma and breast cancer, in pre-clinical testing the drug has been shown to kill many other types of cancer. Additional clinical testing for treatment of primary and metastatic liver cancers is expected to begin later this year or early in 2008.

For more information, log on to http://www.pvct.com.


'/>"/>
SOURCE Provectus Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
2. IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
3. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
4. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
5. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
6. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
7. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
8. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
9. Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published
10. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
11. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
(Date:4/28/2016)... Calif. , April 28, 2016  Marking ... widely accessible breast and ovarian cancer risk test, ... panel analyzing 30 genes that highly impact the ... women. Available today, the Color Test analyzes hereditary ... prostate, stomach, and uterine cancers. The Color Test ...
(Date:4/28/2016)... , April 28, 2016  The blood testing ... million dollars, according to Kalorama Information and The Freedonia ... immunoassays and nucleic acid testing.  The healthcare research firm ... progress in developing blood collection stations and in improving ... in Kalorama Information,s report, Blood Testing Market ...
Breaking Medicine Technology:
(Date:4/30/2016)... , ... April 30, 2016 , ... ... announced RANKED Health , a program to critically evaluate and rank health-focused ... of the program is to provide independent, unbiased and accurate information to help ...
(Date:4/30/2016)... ... 30, 2016 , ... Orlando-based Maximized Living has selected Dr. Nick Wilson of ... Under the care of Maximized Living doctors at the London Olympics in 2012, ... Living is sending the largest contingent of elite chiropractors to Rio to support and ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... the Accreditation Council for Graduate Medical Education (ACGME) that it has received accreditation ... the first accreditation of three residency programs that Memorial is currently pursuing, including ...
(Date:4/29/2016)... ... 29, 2016 , ... Dr. Bernie Siegel, (M.D.) ... MEDICINE and MIRACLES") addresses touchy topics related to Death live on Dr. ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians and ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Spine Team Texas, ... is proud to announce one of their physicians has been invited to be a ... (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. ...
Breaking Medicine News(10 mins):